Sorafenib Induced Hand and Foot Syndrome

Abstract

Sorafenib a multikinase inhibitor has been approved by the FDA for the treatment of thyroid, hepatocellular and renal cell carcinoma. Hand-foot syndrome / palmar -plantar erythrodysesthesia causes redness, swelling and pain on the palms of the hands and / or the soles of the feet. Sometimes blisters also appear. Here, we report a post right hepatectomy hepatocellular carcinoma patient who developed hand and foot syndrome after a dose with sorafenib.